Nicolas Penel

25.3k citations

467 papers · 10.5k indexed · 3 hit papers · h-index 51

Impact in

Oncology top 0.2%
- Vascular Tumors and Angiosarcomas
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Pulmonary and Respiratory Medicine top 0.1%
- Sarcoma Diagnosis and Treatment

Papers in

Oncology 234
- Vascular Tumors and Angiosarcomas 84
- Cancer Immunotherapy and Biomarkers 33
Pulmonary and Respiratory Medicine 270
- Sarcoma Diagnosis and Treatment 204

Co-authors: Jean‐Yves Blay Antoîne Italiano Emmanuelle Bompas Nicolás Isambert Sophie Piperno‐Neumann Christine Chevreau Charles Fournier Florence Duffaud
Journals: Journal of Clinical Oncology (102 papers)Annals of Oncology (58 papers)European Journal of Cancer (20 papers)Investigational New Drugs (16 papers)Critical Reviews in Oncology/Hematology (12 papers)
Partner nations: France United States Spain

In The Last Decade

Nicolas Penel

432 papers receiving 10.3k citations

Hit Papers

align trajectories log scale

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study 2022 · 240 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Annals of Oncology
2018 The Lancet Oncology
2012 The Lancet Oncology

Peers

Countries citing papers authored by Nicolas Penel

Since Specialization

Citations

This map shows the geographic impact of Nicolas Penel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Penel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Penel more than expected).

Fields of papers citing papers by Nicolas Penel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Penel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Penel. The network helps show where Nicolas Penel may publish in the future.

Co-authors

The 25 scholars most cited alongside Nicolas Penel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nicolas Penel Line = papers co-authored together Nicolas Penel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial Annals of Oncology ·Nicolas Penel, Antoîne Italiano, Jennifer Wallet, L. Chaigneau, L. Bratinkova, Nelly Firmin, Sarah Watson, Mariana E Paez, Emmanuelle Bompas, François Bertucci, Mehdi Brahmi, Clémence Henon, Angélique Brunot, Mariella Spalato Ceruso, Gbor Nagy, Esra Ergün, Thomas Ryckewaert, Marie‐Cécile Le Deley, Christophe Perrin, Jean‐Yves Blay	2025	0
2	Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study Cancer ·KaWon Lee, 永田泰史, Hélène Vanacker, Nicolas Penel, Sarah Watson, Benjamin Verret, Mariana E Paez, Emmanuelle Bompas, Waïsse Waïssi, Alexandra Meurgey, Françoise Ducimetière, Jean‐Yves Blay, Armelle Dufresne, Mehdi Brahmi	2025	1
3	Doit-on prendre en compte le stress informationnel de l’oncologue médical ? Bulletin du Cancer ·Nicolas Penel, Audrey Mailliez, Diane Pannier, K M Darshan	2024	0
4	Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer JAMA Oncology ·Randy F. Sweis, Pablo Gajate, Rafael Morales‐Barrera, Jae‐Lyun Lee, Andrea Necchi, Filippo de Braud, Nicolas Penel, Viktor Grünwald, Marco Maruzzo, Johannes Meran, Joana Darc Silva Selvante, Weichao Bao, Yinghui Zhou, Peter Ellinghaus, Jonathan E. Rosenberg	2024	6
5	Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational Studies Clinical Cancer Research ·Chiara Colombo, Arthur Adeodato, Axel Le Cesne, Francesco Barretta, Jean‐Yves Blay, Dirk J. Grünhagen, Nicolas Penel, B. Guru Sri, Marco Fiore, Elena Palassini, Giovanni Grignani, Francesco Tolomeo, Paola Collini, Alessandra Merlini, Federica Perrone, Silvia Stacchiotti, Cornelis Verhoef, (unknown), Sylvie Bonvalot, (unknown), Alessandro Gronchi	2024	2
6	Apport de l’IRM corps entier au bilan initial du liposarcome myxoïde Bulletin du Cancer ·Matthias Czerwonka, Mao-rong Liu, KR Leiby, Gauthier Decanter, Par Julio Aires, Nicolas Penel, L. Ceugnart, S. Taïeb, A. (Apriani ) Riyanti	2023	1
7	Pain in desmoid‐type fibromatosis: Prevalence, determinants and prognosis value International Journal of Cancer ·Nicolas Penel, Sylvie Bonvalot, Marie‐Cécile Le Deley, Antoîne Italiano, Camille Tlemsani, Diane Pannier, KR Leiby, Jean‐Emmanuel Kurtz, Maud Toulmonde, Badamkhand Batkhuu, Daniel Orbach, Pascale Dubray‐Longeras, Benjamin Verret, François Bertucci, Cécile Guillemet, Guojun Han, Armelle Dufresne, Jean‐Yves Blay, L. Rosenkewitsch	2023	8
8	Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study British Journal of Cancer ·Florence Duffaud, Jean‐Yves Blay, Axel Le Cesne, Christine Chevreau, Pascaline Boudou‐Rouquette, Elsa Kalbacher, Nicolas Penel, Christophe Perrin, Valérie Laurence, Emmanuelle Bompas, Esma Saâda-Bouzid, Corinne Delcambre, François Bertucci, Mathilde Cancel, Camille Schiffler, Laure Monard, Corinne Bouvier, Vincent Vidal, Nathalie Gaspar, Sylvie Chabaud	2023	17
9	Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours European Journal of Cancer ·AR Jo, Peter Grimison, Christine Chevreau, Silvia Stacchiotti, Sophie Piperno‐Neumann, Axel Le Cesne, Virginia Ferraresi, Antoîne Italiano, Florence Duffaud, Nicolas Penel, J.A. Rivera, Sylvie Chabaud, L. van der Heijden, David Pérol, Michiel A. J. van de Sande, Jean‐Yves Blay, Hans Gelderblom	2022	17
10	Senescence Induced by UVB in Keratinocytes Impairs Amino Acids Balance Journal of Investigative Dermatology ·Xing Yao, Priya Kundra, M.A. Margoob, Seda ERCAN, S. Tykhovod, Anne-Catherine Wéra, 朋鑫高, Antoine Fattaccioli, Sophie Burteau, Catherine Demazy, Maude Fransolet, Rewina Bedemariam, Nathalie Martin, David Fierro, Gauthier Decanter, Nicolas Penel, Marina Bury, Olivier Pluquet, Marjan Garmyn, Florence Debacq‐Chainiaux	2022	22
11	Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group International Journal of Cancer ·Pascaline Boudou‐Rouquette, E. Martin, Emmanuelle Kempf, Nicolas Penel, Maud Toulmonde, Emmanuelle Bompas, Florence Duffaud, Nelly Firmin, François Bertucci, Jean‐Emmanuel Kurtz, L. Chaigneau, Nicolás Isambert, Esma Saâda-Bouzid, Pascale Dubray‐Longeras, Fréderique Larousserie, Philippe Anract, Christine Chevreau, Jean‐Yves Blay, Sophie Piperno‐Neumann, (unknown)	2021	1
12	Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM) BMC Cancer ·Brice Amadéo, Nicolas Penel, Jean‐Michel Coindre, Isabelle Ray‐Coquard, Karine Ligier, Patricia Delafosse, Anne‐Marie Bouvier, Sandrine Plouvier, Lim Yoo, Aude Lacourt, Gaëlle Coureau, Alain Monnereau, Simone Mathoulin‐Pélissier, Emmanuel Désandes	2020	32
13	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial Cancers ·Ian Chau, Nicolas Penel, Andres O. Soriano, Hendrik‐Tobias Arkenau, Jennifer L. Cultrera, Rafael Santana-Dávila, Emiliano Calvo, Christophe Le Tourneau, Lars Zender, Johanna C. Bendell, Gu Mi, Ling Gao, Samuel McNeely, Joana Oliveira, David Ferry, Roy S. Herbst, Charles S. Fuchs	2020	22
14	Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study Clinical Cancer Research ·Maud Toulmonde, Jean‐Yves Blay, Olivier Bouché, Olivier Mir, Nicolas Penel, Nicolás Isambert, Florence Duffaud, Emmanuelle Bompas, Vilius Dranseika, Romain Boidot, Дудко Григорий Алексеевич, François Ghiringhelli, Carlo Lucchesi, Carine Bellera, François Le Loarer, Antoîne Italiano	2019	14
15	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study European Journal of Cancer ·Axel Le Cesne, Perrine Marec‐Bérard, Jean‐Yves Blay, Nathalie Gaspar, François Bertucci, Nicolas Penel, Emmanuelle Bompas, Sophie Cousin, Maud Toulmonde, Alban Bessede, Wolf H. Fridman, Catherine Sautès‐Fridman, Michèle Kind, François Le Loarer, M. Pulido, Antoîne Italiano	2019	114
16	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome Scientific Reports ·Carolina Gómez Rodríguez, Antoîne Italiano, Valérie Laurence, Nicolas Penel, Audrey Lardy-Cléaud, Olivier Mir, Christine Chevreau, François Bertucci, Emmanuelle Bompas, L. Chaigneau, T.M. Il'yuchenok, Thomas Ryckewaert, Sarah Dumont, Pierre Méeus, Dominique Ranchère, Jean‐Yves Blay, Philippe A. Cassier	2017	8
17	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial The Lancet Oncology ·Axel Le Cesne, Jean‐Yves Blay, Julien Dômont, Emmanuelle Tresch‐Bruneel, Christine Chevreau, François Bertucci, Corinne Delcambre, Esma Saâda-Bouzid, Sophie Piperno‐Neumann, Jacques‐Olivier Bay, Olivier Mir, Isabelle Ray‐Coquard, Thomas Ryckewaert, Thibaud Valentin, Nicolás Isambert, Antoîne Italiano, Stéphanie Clisant, Nicolas Penel	2015	63
18	Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study Clinical Cancer Research ·Víctor Moreno, David Olmos, Carlos Gomez‐Roca, Philippe A. Cassier, Rafael Morales‐Barrera, Bierma-Zeinstra SMA, Elisa Gallerani, André T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile E. Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye	2014	14
19	Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO) The Oncologist ·Isabelle Ray‐Coquard, Antoîne Italiano, Emmanuelle Bompas, Axel Le Cesne, Y Robin, Christine Chevreau, Jacques‐Olivier Bay, Guilhem Bousquet, Sophie Piperno‐Neumann, Nicolás Isambert, L. Lemaître, Charles Fournier, Eric Gauthier, Olivier Collard, Didier Cupissol, Stéphanie Clisant, Jean‐Yves Blay, Nicolas Penel, (unknown)	2012	148
20	Fréquence des génopathies et des antécédents carcinologiques chez 493 adultes atteints de sarcomes viscéraux ou des tissus mous Bulletin du Cancer ·Nicolas Penel, Frédérique Depain-Delmotte, M O Vilain, L. Vanseymortier, L. Ceugnart, S. Taïeb, X. Mirabel, 邓启华, Ali Asghar Akbarian Servin Baghi, Marie‐Christine Baranzelli, F. Pichon, C. Nüesch, Y Robin, Éric Lartigau	2003	10

About Nicolas Penel

Nicolas Penel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Gastroenterology, Rheumatology and Pathology and Forensic Medicine, having authored 467 papers that have together received 10.5k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (204 papers), Vascular Tumors and Angiosarcomas (84 papers), Cardiac tumors and thrombi (57 papers), Cancer Genomics and Diagnostics (42 papers), Soft tissue tumor case studies (37 papers), Lymphoma Diagnosis and Treatment (35 papers), Cancer Immunotherapy and Biomarkers (33 papers) and Gastrointestinal Tumor Research and Treatment (31 papers). The work is most often cited by research in Oncology (5.7k citations), Pulmonary and Respiratory Medicine (6.0k citations), Rheumatology (1.9k citations), Pathology and Forensic Medicine (1.6k citations) and Cardiology and Cardiovascular Medicine (1.9k citations). Nicolas Penel has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Jean‐Yves Blay, Antoîne Italiano, Emmanuelle Bompas, Nicolás Isambert, Sophie Piperno‐Neumann, Christine Chevreau, Charles Fournier, Florence Duffaud, Axel Le Cesne and Stéphanie Clisant. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Investigational New Drugs and Critical Reviews in Oncology/Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact